HCW Biologics Inc. (HCWB)

US — Healthcare Sector
Peers: MNOV  CLYM  MOLN  CSBR  ABVC  RNXT  KTTA  RNAZ  EVAX 

Automate Your Wheel Strategy on HCWB

With Tiblio's Option Bot, you can configure your own wheel strategy including HCWB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HCWB
  • Rev/Share 0.4679
  • Book/Share -0.0292
  • PB -113.3721
  • Debt/Equity -123.5512
  • CurrentRatio 0.1079
  • ROIC -1.4473

 

  • MktCap 8401836.0
  • FreeCF/Share -7.1389
  • PFCF -0.6611
  • PE -0.2734
  • Debt/Assets 0.2221
  • DivYield 0
  • ROE 3.4005

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
HCWB
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.

Read More
image for news HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

About HCW Biologics Inc. (HCWB)

  • IPO Date 2021-07-20
  • Website https://www.hcwbiologics.com
  • Industry Biotechnology
  • CEO Hing C. Wong
  • Employees 36
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.